Ultrasound Denervation Product
Employees: 11-50
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
Mentions in press and media 16
| Date | Title | Description |
| 22.01.2025 | Health | Keeping blood pressure under control is critical. There’s a new option for tough cases | And only a fraction of patients have their hypertension well-controlled, meaning there’s a need for novel strategies. The Food and Drug Administration approved that “renal denervation” option about a year ago, based on studies showing a mod... |
| 24.08.2023 | ReCor Medical wins FDA panel nod for its renal denervation system | This ReCor Medical illustration shows the Paradise renal denervation catheter during the procedure. The red circle indicates ultrasound-generated energy producing heat for denervation, while the blue circles illustrate cooling from circulat... |
| 19.09.2022 | ReCor Medical ultrasound renal denervation trial meets primary efficacy endpoint | This ReCor Medical illustration shows the Paradise renal denervation catheter during the procedure. The red circle indicates ultrasound-generated energy producing heat for denervation, while the blue circles illustrate cooling from circulat... |
| 17.05.2021 | ReCor Medical Announces Results from Landmark RADIANCE-HTN TRIO Study, Showing Clinically Significant Blood Pressure Reduction with the Paradise Ultrasound RDN System in Patients with Resistant Hypert... | PALO ALTO, Calif., May 17, 2021 /PRNewswire/ -- ReCor Medical, Inc. ("ReCor"), a wholly-owned subsidiary of Otsuka Medical Devices Co., Ltd., today presented the primary endpoint data from the randomized sham-controlled RADIANCE-H... |
| 11.07.2018 | Term Sheet — Wednesday, July 11 | 5 Qs WITH A DEALMAKER Even though Polina is out, she prepared this Q&A below for Term Sheet. Please do continue sending deals this week to Lucinda.shen@fortune.com. Paid Content Securing the enterprise without boundaries From ExtraHop M... |
| 10.07.2018 | Sofinnova Partners Sells ReCor Medical to Otsuka Holdings | Sofinnova Partners, a Paris, France-based venture capital firm specialized in Life Sciences, announced the sale of its portfolio company ReCor Medical, a Palo Alto, CA and Sandwich, Kent, UK-based medical device company specialized in the t... |
| 07.04.2016 | ReCor Medical enrolls first patients for study to test device designed to treat hypertension | The company raised a $15 million Series D round in April 2015, and it won an investigation device exemption from the FDA for a trial that took place in February. ReCor does have some significant potential competition in the area, though. Bo... |
| 13.04.2015 | ReCor Medical raises $15M for ultrasound RDN | A Japanese healthcare conglomerate is the lead investor ReCor Medical‘s $15 million Series D round ReCor plans to use to back a U.S. clinical trial of its ultrasound renal denervation device. Otsuka Holdings (TYO:4578) was joined by Sofinno... |
| 23.10.2014 | Stealth hypertension startup Sympara Medical raises nearly $6m | Stealthy Sympara Medical quietly secured $5.5 million in funding from a handful of investors for the hypertension device it’s developing. San Francisco-based Sympara disclosed the funding in a regulatory filing, after recording $4.3 million... |
| 28.02.2014 | Still in the renal denervation space? Startups, consider adaptive trial design, CRO says | For instance, if a sub-population of patients seems to respond with much more efficacious outcomes than the whole population early on, the trial can be adjusted to focus just on those patients. For startups, Dentry-Mabry said, it can be att... |
Show more